MXPA03009278A - Farmacos antiangiogenicos peptidos. - Google Patents

Farmacos antiangiogenicos peptidos.

Info

Publication number
MXPA03009278A
MXPA03009278A MXPA03009278A MXPA03009278A MXPA03009278A MX PA03009278 A MXPA03009278 A MX PA03009278A MX PA03009278 A MXPA03009278 A MX PA03009278A MX PA03009278 A MXPA03009278 A MX PA03009278A MX PA03009278 A MXPA03009278 A MX PA03009278A
Authority
MX
Mexico
Prior art keywords
antiangiogenic drugs
peptide
peptide antiangiogenic
angiogenesis
inhibiting
Prior art date
Application number
MXPA03009278A
Other languages
English (en)
Inventor
Fortuna Haviv
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MXPA03009278A publication Critical patent/MXPA03009278A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion expone peptidos que son utiles en la inhibicion de angiogenasis. Tambien se exponen composiciones inhibidoras de angiogenesis y metodos para la inhibicion de angiogenesls en un mamifero.
MXPA03009278A 2001-04-11 2002-04-10 Farmacos antiangiogenicos peptidos. MXPA03009278A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/832,733 US20020183242A1 (en) 2001-04-11 2001-04-11 Peptide antiangiogenic drugs
PCT/US2002/011027 WO2002083065A2 (en) 2001-04-11 2002-04-10 Peptide antiangiogenic drugs

Publications (1)

Publication Number Publication Date
MXPA03009278A true MXPA03009278A (es) 2004-03-10

Family

ID=25262479

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009278A MXPA03009278A (es) 2001-04-11 2002-04-10 Farmacos antiangiogenicos peptidos.

Country Status (10)

Country Link
US (1) US20020183242A1 (es)
EP (1) EP1429796A4 (es)
JP (1) JP2005510452A (es)
AU (1) AU2002303278A1 (es)
BR (1) BR0205983A (es)
CA (1) CA2443733A1 (es)
MX (1) MXPA03009278A (es)
PE (1) PE20021078A1 (es)
UY (1) UY27254A1 (es)
WO (1) WO2002083065A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045477A1 (en) * 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
JP5167473B2 (ja) * 2005-03-03 2013-03-21 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管新生化合物
JP5890312B2 (ja) 2009-10-09 2016-03-22 ザフゲン，インコーポレイテッド 肥満治療に用いられるスルホン化合物
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
US20130023513A1 (en) 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
BR112013018771A2 (pt) 2011-01-26 2019-09-17 Zafgen Inc compostos de tetrazol e métodos para fazer e usar os mesmos
BR112013028534A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
MX343688B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
US9187494B2 (en) 2011-05-06 2015-11-17 Zafgen, Inc. Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
MX2014008705A (es) 2012-01-18 2015-02-05 Zafgen Inc Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
WO2013109739A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
BR112014028041A2 (pt) 2012-05-08 2017-06-27 Zafgen Inc tratamento de obesidade hipotalâmica com inibidores de metap2
WO2013169860A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
CA2890344A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
KR20150079952A (ko) 2012-11-05 2015-07-08 자프겐 인크. 트리시클릭 화합물 및 그의 제조 및 사용 방법
BR112015010196A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc métodos de tratar doença do fígado
CA2904353A1 (en) 2013-03-14 2014-09-25 Zafgen, Inc. Methods of treating renal disease and other disorders
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200937A (en) * 1988-09-29 1993-04-06 Canon Kabushiki Kaisha Apparatus for and method of recording and/or reproducing information by means of two actuators
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5190918A (en) * 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
PT918795E (pt) * 1997-03-17 2005-02-28 Abbott Lab Droga antiangiogenica para tratar cancro artrite e retinopatia
AU764277B2 (en) * 1998-05-22 2003-08-14 Abbvie Inc. Peptide antiangiogenic drugs
CO5261544A1 (es) * 1999-11-22 2003-03-31 Abbott Lab Peptidos n-alquilados que tienen actividad antiangiogenica
DE60025648T2 (de) * 1999-11-22 2006-09-14 Abbott Laboratories, Abbott Park Peptide mit antiangiogener aktivität

Also Published As

Publication number Publication date
CA2443733A1 (en) 2002-10-24
JP2005510452A (ja) 2005-04-21
UY27254A1 (es) 2002-11-29
WO2002083065A3 (en) 2004-01-08
US20020183242A1 (en) 2002-12-05
EP1429796A4 (en) 2005-01-12
AU2002303278A1 (en) 2002-10-28
EP1429796A2 (en) 2004-06-23
WO2002083065A2 (en) 2002-10-24
BR0205983A (pt) 2006-05-23
PE20021078A1 (es) 2002-12-18

Similar Documents

Publication Publication Date Title
MXPA03009278A (es) Farmacos antiangiogenicos peptidos.
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
MY138074A (en) Somatostatin analogues
EP1402001A4 (en) Antimicrobial peptides and compounds
ATE396204T1 (de) Peptide als antiangiogene arzneimittel
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
MY126868A (en) Suspension comprising oxcarbazepine
WO2001058470A3 (en) Methods for enhancing the bioavailability of a drug
GB9929464D0 (en) Complementary peptide ligande generated from the human genome
GB0100196D0 (en) Peptides
HK1050012A1 (en) Peptides having antiangiogenic activity
ZA200700168B (en) Remodeling and glycoconjugation of peptides
EP1385556A4 (en) PEPTIDE CONJUGATES WITH AFFINITY FOR GASTRIN RECEPTORS
IL150458A0 (en) Novel haptotactic peptides
SG142165A1 (en) Biologically active peptides
MY145375A (en) Pharmaceutical composition
GB0109438D0 (en) Peptides
SI1173194T1 (en) Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation
MY136343A (en) Peptides for treatment of cancer
IL158411A0 (en) Peptides that inhibit viral infections and compositions containing the same
EP1458736A4 (en) RECOMBINANT RINDER THROMBIN
HK1065782A1 (en) Compositions comprising higher diamondoids and processes for their separation
SI1181035T1 (en) Substantially oil-free cyclosporin compositions
GB0117738D0 (en) Peptide screen